Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: MSI-H Colorectal Cancer|Melanoma|Anal Carcinoma|Mesothelioma|Triple Negative Breast Cancer|Lung Adenocarcinoma|Cholangiocarcinoma|Cervical Carcinoma|Kidney Clear Cell Carcinoma|Stomach Adenocarcinoma|Esophageal Adenocarcinoma|Uterine Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Sarcoma|Lung Squamous Cell Carcinoma|Urothelial Carcinoma|Thyroid Carcinoma|Hepatocellular Carcinoma|Uveal Melanoma|HER2-positive Breast Cancer|Pancreatic Adenocarcinoma|Squamous Esophageal Carcinoma|Epithelial Ovarian Cancer|Uterine Carcinosarcoma|Small Cell Lung Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Colorectal Adenocarcinoma|Prostate Adenocarcinoma|Carcinoma of Unknown Primary|Other Histology
Interventions: DRUG: Spartalizumab|DRUG: Tislelizumab
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Novartis